Literature DB >> 24722657

Diagnosis of osteosarcoma in a patient previously treated for Ewing sarcoma.

Manabu Hoshi1, Makoto Ieguchi, Kazumi Yamato, Sadao Tokimasa, Hiroaki Nakamura.   

Abstract

Primary malignant bone tumors, whether Ewing sarcoma or osteosarcoma, are a rare type of tumor. The sequential occurrence of two bone sarcomas, Ewing sarcoma and high-grade osteosarcoma, in the same patient at two different locations is an exceptionally rare phenomenon. We present the case of a 13-year-old girl who presented with a high-grade osteoblastic osteosarcoma of the distal femur, 7 years after treatment for Ewing sarcoma of the left pelvis. She did not receive radiation therapy. Following the recent developing multidisciplinary therapy, long-term follow-up for monitoring latent treatment-related adverse effects may be necessary for survivors of primary malignant bone tumors.

Entities:  

Mesh:

Year:  2014        PMID: 24722657     DOI: 10.1007/s00256-014-1880-z

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  22 in total

1.  Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.

Authors:  N M Marina; A S Pappo; D M Parham; A M Cain; B N Rao; C A Poquette; C B Pratt; C Greenwald; W H Meyer
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  Case report: A rare case of Ewing's sarcoma and osteosarcoma at different sites 10 years apart.

Authors:  Harish S Hosalkar; Alfred Atanda; Julieta Barroeta; Jesse T Torbert; Richard D Lackman
Journal:  Clin Orthop Relat Res       Date:  2005-05       Impact factor: 4.176

3.  Intraarterial Cisplatin and caffeine with/without Doxorubicin for musculoskeletal high-grade spindle-cell sarcoma.

Authors:  H Tsuchiya; K Tomita; H Yasutake; Y Takagi; S Katsuo; Y Tokuumi; M Sugihara
Journal:  Oncol Rep       Date:  1994-01       Impact factor: 3.906

4.  Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

Authors:  Christine Juergens; Claire Weston; Ian Lewis; Jeremy Whelan; Michael Paulussen; Odile Oberlin; Jean Michon; Andreas Zoubek; Herbert Juergens; Alan Craft
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

5.  Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience.

Authors:  P Rosito; A F Mancini; R Rondelli; M E Abate; A Pession; L Bedei; G Bacci; P Picci; M Mercuri; P Ruggieri; G Frezza; M Campanacci; G Paolucci
Journal:  Cancer       Date:  1999-08-01       Impact factor: 6.860

6.  Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study.

Authors:  R G Evans; M E Nesbit; E A Gehan; L A Garnsey; O Burgert; T J Vietti; A Cangir; M Tefft; P Thomas; F B Askin
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

7.  Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).

Authors:  Alessandra Longhi; Stefano Ferrari; Angela Tamburini; Roberto Luksch; Franca Fagioli; Gaetano Bacci; Cristina Ferrari
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

8.  Second cancers in patients with the Ewing sarcoma family of tumours.

Authors:  Fariba Navid; Catherine Billups; Tiebin Liu; Matthew J Krasin; Carlos Rodriguez-Galindo
Journal:  Eur J Cancer       Date:  2008-03-18       Impact factor: 9.162

9.  Bone sarcomas linked to radiotherapy and chemotherapy in children.

Authors:  M A Tucker; G J D'Angio; J D Boice; L C Strong; F P Li; M Stovall; B J Stone; D M Green; F Lombardi; W Newton
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

10.  Sequential Ewing's sarcoma and osteosarcoma.

Authors:  Vivek Sharma; Alvin H Crawford; Jonathan Evans; Margaret H Collins
Journal:  J Pediatr Orthop B       Date:  2008-11       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.